Source: IGF Oncology
The
mission of IGF Oncology is to develop and bring to patients new
targeted cancer chemotherapy drugs that have reduced side effects and
improved effectiveness compared to existing chemotherapy cancer drugs.
Our
lead drug is IGF-MTX and we are in clinical trials at Mayo Clinic and
elsewhere in a deadly blood cancer called Myelodysplastic Syndrome
(MDS). There are currently no very effective drugs for MDS blood cancer.
If our drug proves to have even modest efficacy, it will be more
effective than anything on the market and will win FDA approval. Once
IGF-MTX proves effective against MDS, we will target other cancers.
Clinical
Trials
Dr. Hugh McTavish is a practicing patent attorney and a Ph.D. biochemist with extensive experience in the laboratory. He is also the inventor of the company’s technology. Dr. McTavish is the lead author of several refereed scientific publications, and the inventor of several issued patents and pending patent applications. He received his Ph.D. in biochemistry from the University of Minnesota in 1992, and his J.D. from the University of Minnesota in 2001.
Dr Dudek has over 18 years of cancer clinical research experience, over 18 years in the clinical management of mesothelioma, lung cancer, kidney cancer, and malignant melanoma, and over 13 years in the field of tumor angiogenesis, signal transduction, and cancer immunotherapy. His expertise is in design and execution of clinical trials for cancer therapy with a special interest in the development of novel cancer therapeutics. He has 17 years of serving in several leadership positions in clinical trial offices at the University of Minnesota and the University of Illinois. He chairs and manages a broad range of clinical trials (from phase 1 through phase 3, from cooperative group, investigator-initiated, and industry sponsored studies) that are either therapeutic or non-therapeutic studies.
Management Team
 |
Hugh McTavish
|
Dr. Hugh McTavish is a practicing patent attorney and a Ph.D. biochemist with extensive experience in the laboratory. He is also the inventor of the company’s technology. Dr. McTavish is the lead author of several refereed scientific publications, and the inventor of several issued patents and pending patent applications. He received his Ph.D. in biochemistry from the University of Minnesota in 1992, and his J.D. from the University of Minnesota in 2001.
 |
Arkadiusz Dudek
|
Arkadiusz Dudek is
Professor of Hematology/Oncology and Director of Oncology Clinical Trials at
the University of Illinois Chicago.
Dr Dudek has over 18 years of cancer clinical research experience, over 18 years in the clinical management of mesothelioma, lung cancer, kidney cancer, and malignant melanoma, and over 13 years in the field of tumor angiogenesis, signal transduction, and cancer immunotherapy. His expertise is in design and execution of clinical trials for cancer therapy with a special interest in the development of novel cancer therapeutics. He has 17 years of serving in several leadership positions in clinical trial offices at the University of Minnesota and the University of Illinois. He chairs and manages a broad range of clinical trials (from phase 1 through phase 3, from cooperative group, investigator-initiated, and industry sponsored studies) that are either therapeutic or non-therapeutic studies.
 |
Ronald Way
|
Former U.S.
Senate staffer and journalist. Current board member for several medical device
and pharmaceutical companies.
 |
Kathleen Littrell
|
Has more than 20
years of experience in all phases of clinical trials.
No comments:
Post a Comment